| Valvoline Inc. Announces Kevin Willis as Chief Financial Officer |
Valvoline Inc. announces that Kevin Willis will become the Company's next Chief Financial Officer (CFO), effective May 19, 2025 Current CFO, Mary Meixelsperger, whose planned retirement was announced October 2024, will remain with the company through a transition period LEXINGTON, Ky. , May 8, 2025 /PRNewswire/ -- Valvoline Inc. (NYSE: VVV), the quick, easy, trusted leader in preventive automotive maintenance, today announced that Kevin Willis will succeed Mary Meixelsperger as Valvoline Inc.'s Chief Financial Officer effective May 19. |
prnewswire.com |
2025-05-08 10:45:00 |
Czytaj oryginał (ang.) |
| Ashland board authorizes quarterly dividend |
WILMINGTON, Del., May 06, 2025 (GLOBE NEWSWIRE) -- The board of directors of Ashland Inc. (NYSE: ASH) has declared a quarterly cash dividend of $0.415 cents per share on the company's common stock which represents a 2.5 percent increase from the previous quarter. |
globenewswire.com |
2025-05-06 21:15:00 |
Czytaj oryginał (ang.) |
| Ashland's Q2 Earnings and Revenues Miss Estimates, Down Y/Y |
ASH's fiscal second-quarter sales are adversely impacted by the portfolio optimization actions. |
zacks.com |
2025-05-06 13:50:40 |
Czytaj oryginał (ang.) |
| Ashland announces executive leadership changes |
WILMINGTON, Del., May 05, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) announced today that Kevin Willis, senior vice president and chief financial officer, has decided to leave Ashland to pursue another opportunity. His last day with the company will be May 16, 2025. |
globenewswire.com |
2025-05-05 21:00:00 |
Czytaj oryginał (ang.) |
| Ashland, Inc. (ASH) Q2 2025 Earnings Call Transcript |
Ashland, Inc. (NYSE:ASH ) Q2 2025 Earnings Conference Call May 1, 2025 10:00 AM ET Company Participants William Whitaker - VP, Finance & Director, IR Guillermo Novo - Chairman & CEO John Willis - SVP, CFO & Principal Accounting Officer Alessandra Faccin - SVP and GM, Life Sciences and Intermediates James Minicucci - SVP & GM, Personal Care Dago Caceres - SVP & General Manager, Specialty Additives Conference Call Participants Kevin Estok - Jefferies Bhavesh Lodaya - BMO Capital Markets Jeff Zekauskas - JPMorgan David Begleiter - Deutsche Bank Josh Spector - UBS Michael Sison - Wells Fargo John Roberts - Mizuho Mike Harrison - Seaport Research Partners Operator Hello, and welcome to Ashland's Second Quarter Fiscal Year 2025 Earnings Conference Call and Webcast. [Operator Instructions] I would now like to turn the conference over to William Whitaker. |
seekingalpha.com |
2025-05-01 23:48:04 |
Czytaj oryginał (ang.) |
| Ashland (ASH) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates |
The headline numbers for Ashland (ASH) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2025-05-01 00:35:32 |
Czytaj oryginał (ang.) |
| Ashland (ASH) Lags Q2 Earnings and Revenue Estimates |
Ashland (ASH) came out with quarterly earnings of $0.99 per share, missing the Zacks Consensus Estimate of $1.10 per share. This compares to earnings of $1.27 per share a year ago. |
zacks.com |
2025-04-30 23:50:32 |
Czytaj oryginał (ang.) |
| Ashland reports second quarter fiscal 2025 results and revises full-year outlook |
WILMINGTON, Del., April 30, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) today announced financial results1 for the second quarter of fiscal year 2025, which ended March 31, 2025, and revised its full-year fiscal 2025 outlook. Ashland, a global additives and specialty ingredients company, holds leadership positions in high-quality, consumer-focused markets including pharmaceuticals, personal care and architectural coatings. |
globenewswire.com |
2025-04-30 21:01:00 |
Czytaj oryginał (ang.) |
| Ashland Place Completes Two New Financing Facilities for Sirius Aviation Capital |
NEW YORK , April 29, 2025 /PRNewswire/ -- Ashland Place Finance LLC ("Ashland Place"), a commercial aviation financing platform, today announced the completion of two new facilities for Sirius Aviation Capital Holdings Limited ("Sirius"), a global aircraft lessor based in Abu Dhabi Global Market. Both A320-200s, the aircraft are currently operating on lease to ANA's Peach Aviation Limited ("Peach") in Japan and Controladora Vuela Compañía de Aviación, S.A.B. |
prnewswire.com |
2025-04-29 13:00:00 |
Czytaj oryginał (ang.) |
| Earnings Preview: Ashland (ASH) Q2 Earnings Expected to Decline |
Ashland (ASH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-04-23 15:07:53 |
Czytaj oryginał (ang.) |
| Ashland sets date for second-quarter fiscal 2025 earnings release and conference call webcast |
WILMINGTON, Del., April 17, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) today announced plans to issue its second-quarter fiscal 2025 earnings release at approximately 5 p.m. ET on Wednesday, April 30, 2025. The company's live webcast with securities analysts will include an executive summary and detailed remarks. The live webcast will take place at 10 a.m. ET on Thursday, May 1. Simultaneously, the company will post a slide presentation in the Investor Relations section of its website at http://investor.ashland.com. |
globenewswire.com |
2025-04-17 10:30:00 |
Czytaj oryginał (ang.) |
| Ashland Wraps Up Expansion of Pharmaceutical Plant in Brazil |
ASH is investing in modernizing equipment for microbial protection in personal care applications at its Technical Center in Sao Paulo. |
zacks.com |
2025-04-03 17:05:35 |
Czytaj oryginał (ang.) |
| Ashland expands pharmaceutical plant for Aquarius™ tablet coatings and commissions new microbial protection capability in Brazil, demonstrating strategy to globalize, innovate, and invest |
Increased production capacity and market presence expected to drive competitive position and organic growth; follows previous investments in Ireland and China Increased production capacity and market presence expected to drive competitive position and organic growth; follows previous investments in Ireland and China |
globenewswire.com |
2025-04-01 10:59:00 |
Czytaj oryginał (ang.) |
| Ashland to host 2025 Innovation Day for analysts and investors |
WILMINGTON, Del., March 28, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) is hosting an Innovation Day for analysts and investors at the company's Bridgewater, New Jersey facility, Thursday, May 29, 2025. The event will showcase the enhanced capabilities and expanded applications of Ashland's scalable technology platforms. Registration is required, with options to attend via live webcast or in person. |
globenewswire.com |
2025-03-28 08:59:00 |
Czytaj oryginał (ang.) |
| Ashland Wraps Up Divestment of Avoca Business to Mane |
ASH closes the sales of its Avoca business, the last entity remaining from the Pharmachem acquisition. |
zacks.com |
2025-03-18 12:20:20 |
Czytaj oryginał (ang.) |
| Ashland completes sale of Avoca business to Mane |
Wilmington, Del., March 17, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) announced today that it has completed the sale of its Avoca business to Mane effective March 14, 2025. Financial terms of the transaction were not disclosed. |
globenewswire.com |
2025-03-17 09:00:00 |
Czytaj oryginał (ang.) |
| Ashland Presents Attractive Upside Emerging From The Downcycle |
Ashland is generating attractive free cash flow and is well-positioned to achieve its 2027 target of $600 million EBITDA and 50% FCF conversion rate. Despite the stock selling off over the last 8 months, Ashland's strategic acquisitions and divestitures have strengthened its market position, with a focus on high-margin, patent-protected products. Ashland's strong balance sheet, low leverage, and fixed-rate debt provide stability and flexibility to navigate the current downcycle in the specialty chemicals sector. |
seekingalpha.com |
2025-02-27 16:14:55 |
Czytaj oryginał (ang.) |
| TScan Therapeutics: Finding Their Footing After An Eventful ASH Meeting |
TScan Therapeutics is developing engineered T cell receptor therapies, with TSC-101 targeting HA-2 for acute leukemia, showing promising phase 1 results but potential GvHD risks. TCRX's financials are strong, with $133.1 million in cash and equivalents, funding operations into Q4 2026, despite high clinical development costs. The market undervalues TCRX stock, trading at less than half its Q3 assets, presenting an opportunity amid current biotech pessimism. |
seekingalpha.com |
2025-02-10 05:14:00 |
Czytaj oryginał (ang.) |
| Ashland's Earnings Outpace Estimates, Revenues Miss in Q1 |
Organic sales volume growth in ASH's Personal Care, Specialty Additives and Intermediates segments largely offset lower volumes in Life Sciences in Q1. |
zacks.com |
2025-01-30 09:31:08 |
Czytaj oryginał (ang.) |
| Ashland Inc. (ASH) Q1 2025 Earnings Call Transcript |
Ashland Inc. (NYSE:ASH ) Q1 2025 Earnings Conference Call January 29, 2025 9:00 AM ET Company Participants William Whitaker - VP, Finance and Director, IR Guillermo Novo - Chair and CEO Kevin Willis - CFO Alessandra Faccin - SVP and GM, Life Sciences and Intermediates Jim Minicucci - SVP and GM, Personal Care Dago Caceres - SVP and GM, Specialty Additives Conference Call Participants Michael Sison - Wells Fargo Chris Parkinson - Wolfe Research John Roberts - Mizuho David Begleiter - Deutsche Bank Jeff Zekauskas - JPMorgan Mike Harrison - Seaport Research Partners Bhavesh Lodaya - BMO Capital Markets Josh Spector - UBS Operator Good day and thank you for standing by. Welcome to the Ashland Inc. First Quarter 2025 Earnings Conference Call. |
seekingalpha.com |
2025-01-29 23:24:55 |
Czytaj oryginał (ang.) |
| New Strong Sell Stocks for January 29th |
ARCAY, ASH and DNKEY have been added to the Zacks Rank #5 (Strong Sell) List on January 29, 2024. |
zacks.com |
2025-01-29 06:20:14 |
Czytaj oryginał (ang.) |
| Here's What Key Metrics Tell Us About Ashland (ASH) Q1 Earnings |
Although the revenue and EPS for Ashland (ASH) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2025-01-28 22:01:10 |
Czytaj oryginał (ang.) |
| Ashland (ASH) Surpasses Q1 Earnings Estimates |
Ashland (ASH) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.20 per share. This compares to earnings of $0.45 per share a year ago. |
zacks.com |
2025-01-28 21:26:13 |
Czytaj oryginał (ang.) |
| Ashland reports financial results for first quarter fiscal 20251, reiterates outlook for full-year fiscal 2025 |
WILMINGTON, Del., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) today announced financial results1 for the first quarter of fiscal year 2025, which ended December 31, 2024, and issued its full-year fiscal 2025 outlook. Ashland, a global additives and specialty ingredients company, holds leadership positions in high-quality, consumer-focused markets including pharmaceuticals, personal care and architectural coatings. |
globenewswire.com |
2025-01-28 19:01:00 |
Czytaj oryginał (ang.) |
| Stay Ahead of the Game With Ashland (ASH) Q1 Earnings: Wall Street's Insights on Key Metrics |
Beyond analysts' top -and-bottom-line estimates for Ashland (ASH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024. |
zacks.com |
2025-01-23 12:21:40 |
Czytaj oryginał (ang.) |
| Forget The S&P 500 - 3 Small Dividend Stocks At Big Discounts |
President Trump inherits a historically expensive stock market, with the Shiller P/E ratio indicating potentially subdued long-term returns for the S&P 500. Despite high valuations, opportunities exist, especially in smaller and mid-cap stocks, which are undervalued compared to large-cap stocks. The market's top-heavy nature, driven by FANG+ stocks, presents a risk/reward shift, making smaller companies more attractive. |
seekingalpha.com |
2025-01-23 09:30:00 |
Czytaj oryginał (ang.) |
| Analysts Estimate Ashland (ASH) to Report a Decline in Earnings: What to Look Out for |
Ashland (ASH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-01-21 13:11:41 |
Czytaj oryginał (ang.) |
| Ashland board authorizes quarterly dividend |
WILMINGTON, Del., Jan. 20, 2025 (GLOBE NEWSWIRE) -- The board of directors of Ashland Inc. (NYSE: ASH) has declared a quarterly cash dividend of $0.405 cents per share on the company's common stock. The dividend is payable on March 15, 2025, to stockholders of record at the close of business on March 1, 2025. |
globenewswire.com |
2025-01-20 19:00:00 |
Czytaj oryginał (ang.) |
| Bear of the Day: Ashland Inc (ASH) |
This stock does not have the best looking chart and has seen estimates continue to fall. |
zacks.com |
2025-01-16 10:12:12 |
Czytaj oryginał (ang.) |
| Ashland sets date for first-quarter fiscal 2025 earnings release and conference call webcast |
WILMINGTON, Del., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) today announced plans to issue its first-quarter fiscal 2025 earnings release at approximately 5 p.m. ET on Tuesday, January 28, 2025. The company's live webcast with securities analysts will include an executive summary and detailed remarks. The live webcast will take place at 9 a.m. ET on Wednesday, January 29. Simultaneously, the company will post a slide presentation in the Investor Relations section of its website at http://investor.ashland.com. |
globenewswire.com |
2025-01-14 09:00:00 |
Czytaj oryginał (ang.) |
| New Strong Sell Stocks for January 7th |
ETNB, ATUS and ASH have been added to the Zacks Rank #5 (Strong Sell) List on January 7, 2024. |
zacks.com |
2025-01-07 06:26:06 |
Czytaj oryginał (ang.) |
| Ashland Inks Deal to Sell Avoca Business to Optimize Portfolio |
ASH is set to sell off its remaining Sclareolide business through the divestiture of Avoca to Mane. |
zacks.com |
2024-12-30 13:17:10 |
Czytaj oryginał (ang.) |
| Hematology Oncology of Indiana Physician Research Presented at 66th ASH Annual Meeting |
INDIANAPOLIS, IN., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Board-certified medical oncologists, M. Sarfraz Nawaz, MD and Ruemu E. Birhiray, MD from community oncology practice Hematology Oncology of Indiana (HOI), a partner practice of American Oncology Network (AON) (OTCQX: AONC), presented clinically meaningful and socially impactful research findings at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, held Dec. 7-10 in San Diego. |
globenewswire.com |
2024-12-30 10:00:00 |
Czytaj oryginał (ang.) |
| Ashland signs definitive agreement to sell Avoca business to Mane |
Wilmington, Del., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) announced today that it has signed a definitive agreement to sell its Avoca business to Mane. The transaction is expected to close in the calendar first quarter 2025, subject to the satisfaction of customary closing conditions. |
globenewswire.com |
2024-12-23 19:01:00 |
Czytaj oryginał (ang.) |
| New Strong Sell Stocks for November 18th |
ASH, ARW and AN have been added to the Zacks Rank #5 (Strong Sell) List on November 18, 2024. |
zacks.com |
2024-12-18 09:26:16 |
Czytaj oryginał (ang.) |
| Ashland price target lowered to $85 from $100 at Evercore ISI |
Evercore ISI analyst Eric Boyes lowered the firm's price target on Ashland to $85 from $100 and keeps an In Line rating on the shares as a new analyst took over coverage of the stock and 10 other chemical names. Dissonance between sputtering industrial demand into year-end and prospects for a "less bad" 2025 has "muddled the forward outlook for chemicals investors" and the firm's sense is further EBITDA and EPS cuts coming to Q1 and FY25 "are needed to clear the deck," the analyst says. However, Evercore suspects the stocks "move sharply higher with signs of improving demand, so begin to position accordingly," the analyst added. |
https://thefly.com |
2024-12-17 18:20:34 |
Czytaj oryginał (ang.) |